{"filing":{"accession_number":"0001437749-26-025781","cik":"0001710340","ticker":"ETON","company_name":"Eton Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-07-31","primary_document":"eton20260803_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1710340/000143774926025781/eton20260803_8k.htm"},"events":[{"id":24959,"run_id":22629,"accession_number":"0001437749-26-025781","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Eton Pharmaceuticals entered into a material license agreement on July 31, 2026 to acquire U.S. rights to ASN-001, a late-stage rare disease product candidate from Auson Pharmaceuticals. The transaction involves an upfront payment of $3.0 million, significant milestone payments up to $33.5 million upon FDA approval and sales thresholds, and tiered royalties on future net sales. The acquisition expands Eton's infantile hemangioma franchise and is expected to become the largest revenue-generating product in Eton's portfolio.","company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25669,"accession_number":"0001437749-26-025781","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Eton entered into a material license agreement on July 31, 2026 to acquire U.S. rights to ASN-001, a late-stage rare disease product candidate from Auson Pharmaceuticals. The transaction involves an upfront payment of $3.0 million, significant milestone payments up to $33.5 million upon FDA approval and sales thresholds, and tiered royalties on future net sales. The press release emphasizes this as an \"acquisition\" that \"expands\" Eton's infantile hemangioma franchise and positions the company to address a substantially larger patient population (20,000–30,000 annually) than its existing HEMANGEOL product, with potential to become \"the largest revenue generating product in Eton's portfolio.\" This constitutes a material acquisition of product rights meeting the Item 1.01 threshold.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T03:21:44.829266+00:00","company_name":"","ticker":null,"filing_date":""},{"id":25670,"accession_number":"0001437749-26-025781","item_number":"2.01","item_title":"Completion of Acquisition or Disposition of Assets","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Eton Pharmaceuticals entered into a license agreement on July 31, 2026 to acquire U.S. rights to ASN-001, a late-stage rare disease product candidate from Auson Pharmaceuticals. The press release emphasizes this as an \"acquisition\" that \"adds yet another high-value, late-stage candidate\" to the pipeline and positions the company to address a substantially larger patient population (20,000-30,000 annually) with potential to become \"the largest revenue generating product in Eton's portfolio.\" This is a material acquisition of intellectual property and development rights that expands the company's therapeutic franchise.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T03:21:44.829266+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25669,"accession_number":"0001437749-26-025781","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Eton entered into a material license agreement on July 31, 2026 to acquire U.S. rights to ASN-001, a late-stage rare disease product candidate from Auson Pharmaceuticals. The transaction involves an upfront payment of $3.0 million, significant milestone payments up to $33.5 million upon FDA approval and sales thresholds, and tiered royalties on future net sales. The press release emphasizes this as an \"acquisition\" that \"expands\" Eton's infantile hemangioma franchise and positions the company to address a substantially larger patient population (20,000–30,000 annually) than its existing HEMANGEOL product, with potential to become \"the largest revenue generating product in Eton's portfolio.\" This constitutes a material acquisition of product rights meeting the Item 1.01 threshold.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T03:21:44.829266+00:00","company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","filing_date":"2026-08-05"},{"id":25670,"accession_number":"0001437749-26-025781","item_number":"2.01","item_title":"Completion of Acquisition or Disposition of Assets","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Eton Pharmaceuticals entered into a license agreement on July 31, 2026 to acquire U.S. rights to ASN-001, a late-stage rare disease product candidate from Auson Pharmaceuticals. The press release emphasizes this as an \"acquisition\" that \"adds yet another high-value, late-stage candidate\" to the pipeline and positions the company to address a substantially larger patient population (20,000-30,000 annually) with potential to become \"the largest revenue generating product in Eton's portfolio.\" This is a material acquisition of intellectual property and development rights that expands the company's therapeutic franchise.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T03:21:44.829266+00:00","company_name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","filing_date":"2026-08-05"}]}